GLPwatch
Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US.
JAMA · 2025
Last updated 2026-09-22| Journal | JAMA, 2025 |
|---|---|
| Citations | 43 |
| Relative citation ratio | 11.52 |
| Molecules | semaglutide, tirzepatide |
| Conditions studied | Obesity |
Full record and abstract on PubMed 40299371 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.